Page last updated: 2024-10-15

guanosine monophosphate

Description

Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135398631
CHEMBL ID283807
CHEBI ID17345
SCHEMBL ID5854
SCHEMBL ID19222125
MeSH IDM0009690

Synonyms (73)

Synonym
5'-guanylic acid
CHEBI:17345 ,
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-1,6-dihydro-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl dihydrogen phosphate
guanosine 5'-monophosphoric acid
einecs 201-598-8
guanosine 5'-phosphoric acid
guanidine monophosphate
guanosine 5'-(dihydrogen phosphate)
guanine riboside-5-phosphoric acid
guanosine-monophosphate
ai3-28539
guanosine-phosphate
5gp ,
5'-guanylic acid (8ci,9ci)
e 626
guanosine 5'-monophosphate
guanylate
guanosine monophosphate
85-32-5
C00144
guanosine 5'-phosphate
guanosine-5'-monophosphate
guanylic acid
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate
5'-gmp
xylo-gmp
DB01972
1QK3
2FXV
1W25
1SGX
1G9T
guanosine-5'-phosphate
38CABC90-82D3-4544-9566-34C06A477068
CHEMBL283807 ,
bdbm50010318
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl phosphate
A841293
29593-02-0
unii-16597955ep
16597955ep ,
c10h14n5o8p
guanosine 5' monophosphate
EPITOPE ID:190357
gtpl5123
{[(2r,3s,4r,5r)-5-(2-amino-6-oxo-6,9-dihydro-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
5'-guanylic acid [mi]
ins no.626
ins-626
e-626
AKOS025311571
SCHEMBL5854
DTXSID9044295
RQFCJASXJCIDSX-UUOKFMHZSA-N
((2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9(6h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate
[3h]guanosine monophosphate
guanylsaure
guanosine 5'-phosphorate
CS-0032523
HY-N5134
SCHEMBL19222125
Q422473
128952-18-1
mfcd00057066
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
[(2r,3s,4r,5r)-5-(2-amino-6-hydroxypurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
hyaluronic acid, dimethylsilylene ester
5'-guanosine monophosphate5'-gmp
5'-guanosine monophosphate
guanosine-5'-monophosphate 1000 microg/ml in acetonitrile:water
((2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9(6h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyldihydrogenphosphate
Z2289798741
AKOS040744252

Toxicity

ExcerptReference
" IDX184 was safe and well tolerated; no serious adverse events (SAEs), dose-dependent adverse events (AEs), or dose-limiting toxicities were observed."( Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects.
Chen, J; Khan, S; Mayers, D; Pietropaolo, K; Sullivan-Bólyai, J; Zhou, XJ, 2011
)
" At LC50, CINA was the most toxic (0."( In vitro safety assessment of food ingredients in canine renal proximal tubule cells.
Jeffery, B; Koči, J; Monteiro-Riviere, NA; Riviere, JE, 2015
)
" To better understand the mechanism for adverse events, clinically relevant HCV NI were characterized in biochemical and cellular assays, including assays of decreased viability in multiple cell lines and primary cells, interaction with human DNA and RNA polymerases, and inhibition of mitochondrial protein synthesis and respiration."( Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus.
Ahmadyar, S; Babusis, D; Barauskas, O; Feng, JY; McCutcheon, K; Park, Y; Perron, M; Perry, JK; Ray, AS; Sakowicz, R; Schultz, BE; Stepan, G; Xu, Y; Yu, H, 2016
)
"BMS-986094, a 2'-C-methylguanosine prodrug that was in development for treatment of chronic hepatitis C infection was withdrawn from Phase 2 clinical trials because of unexpected cardiac and renal adverse events."( From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor.
Bounous, D; Clark, S; Davies, M; Gill, M; Graziano, M; Hennan, J; Horn, K; Janovitz, E; Megill, JR; Sanderson, T; White, R, 2017
)
" Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis."( Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs.
Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G, 2017
)
" Motion imaging analysis revealed the difference in cardiotoxicity between the cardiotoxic BMS-986094 and the less toxic sofosbuvir in hiPSC-CMs, with a minimum of 4 days of treatment."( Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes.
Hayashi, S; Kanda, Y; Ono, A; Satsuka, A; Yanagida, S, 2021
)

Pharmacokinetics

ExcerptReference
" Plasma and urine pharmacokinetic sampling was performed over a period of 120 h after dosing."( Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects.
Chen, J; Khan, S; Mayers, D; Pietropaolo, K; Sullivan-Bólyai, J; Zhou, XJ, 2011
)
" A mass balance study of radiolabeled IDX184 and pharmacokinetic studies of IDX184 in portal vein-cannulated monkeys revealed relatively low IDX184 absorption but higher exposure of IDX184 in the portal vein than in the systemic circulation, indicating >90 % of the absorbed dose was subject to hepatic extraction."( Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposure.
Bhadresa, S; Bu, C; Cohen, ML; Gasparac, R; Good, SS; Gupta, K; Mayes, BA; Moussa, A; Pan-Zhou, XR; Rashidzadeh, H; Rush, R; Smith, S, 2016
)
" This article describes a phase 1b study evaluating the safety and pharmacodynamic effects of zagociguat."( Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly.
Borghans, L; Gal, P; Glasser, C; Groeneveld, GJ; Klaassen, ES; Tripp, K; van der Grond, J; van Kraaij, SJW; Winrow, C, 2023
)
" Pharmacodynamic assessments included evaluation of cerebral blood flow, CNS tests, pharmaco-electroencephalography, passive leg movement and biomarkers in blood, CSF and brain."( Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly.
Borghans, L; Gal, P; Glasser, C; Groeneveld, GJ; Klaassen, ES; Tripp, K; van der Grond, J; van Kraaij, SJW; Winrow, C, 2023
)
" No consistent effects of zagociguat on other pharmacodynamic parameters were detected."( Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly.
Borghans, L; Gal, P; Glasser, C; Groeneveld, GJ; Klaassen, ES; Tripp, K; van der Grond, J; van Kraaij, SJW; Winrow, C, 2023
)
" No clear pharmacodynamic effects of zagociguat were detected."( Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly.
Borghans, L; Gal, P; Glasser, C; Groeneveld, GJ; Klaassen, ES; Tripp, K; van der Grond, J; van Kraaij, SJW; Winrow, C, 2023
)

Compound-Compound Interactions

ExcerptReference
" The increase in lifespan (ILS) of mice treated with 5'-DFUR was augmented by the combination with guanosine or inosine in a dose-dependent fashion, and the maximum ILS was about 160% with the combination, while that in the case of 5'-DFUR alone was only 48% in the P388 leukemia system."( Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
Iigo, M; Ishitsuka, H; Miwa, M; Nitta, K, 1987
)
" Sequential cohorts of 20 patients, randomized 16:4 (active:placebo), received IDX184 for 14 days at rising daily doses of 50, 100, 150 or 200 mg in combination with P/R for 14 days."( IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ, 2013
)
"IDX184 in combination with P/R for 14 days was well tolerated and demonstrated greater antiviral activity with more patients achieving undetectable viral load than P/R."( IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ, 2013
)

Bioavailability

ExcerptReference
"These data demonstrate that in vivo adenoviral gene transfer of EC-SOD can reduce corporal superoxide anion levels and raise cavernosal cGMP levels by increasing NO bioavailability thus restoring erectile function in the STZ-diabetic rat."( Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy.
Alvarez, X; Bivalacqua, TJ; Champion, HC; Hellstrom, WJ; Kadowitz, PJ; Kendirci, M; Pradhan, L; Usta, MF, 2005
)

Dosage Studied

ExcerptReference
" However, on increasing the concentrations of these agents, the reversing effect of guanylic acid decreased gradually, the dose-response curves for the two agents being similar."( Effect of bredinin and its aglycone on L5178Y cells.
Hayano, K; Ishida, N; Mizuno, K; Sakaguchi, K; Tsujino, M, 1975
)
" Dose-response curves of these drugs fitted the theoretical dose-response relations, but the curves of ATP and GTP were not significantly altered by propranolol."( Nature of catecholamine-like actions of ATP and other energy rich nucleotides on the bullfrog atrial muscle.
Goto, M; Tsuda, Y; Yatani, A, 1978
)
" Moderate rhinovirus activity was observed for several compounds at nontoxic dosage levels."( Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogues of imidazo[1,2-a]-s-triazine.
Allen, LB; Bartholomew, DG; Kim, SH; Revankar, GR; Robins, RK, 1978
)
" They demonstrate that taurocholate synthesis is increasing rapidly during the final stages of gestation and show that cortisol augments taurocholate synthesis in a dose-response pattern."( Synthesis of taurocholate by rat fetal liver in organ culture: effects of cortisol in vitro.
Graham, TO; Lester, R; Little, JM; Van Thiel, DH, 1979
)
" The effects of the temperature change on dose-response curves for fructose, NH4Cl, and GMP were examined using dogs."( Differential temperature dependence of taste nerve responses to various taste stimuli in dogs and rats.
Kurihara, K; Nakamura, M, 1991
)
" Amiloride shifted the dose-response curves for MSG to a higher concentration region, suggesting that amiloride inhibits the response to MSG in a competitive manner."( Canine taste nerve responses to monosodium glutamate and disodium guanylate: differentiation between umami and salt components with amiloride.
Kurihara, K; Nakamura, M, 1991
)
" The assay for guanylate kinase 1 (GUK 1) activity showed a gene dosage effect and confirmed the regional assignment of this marker in the chromosomal region indicated by data derived from somatic hybrids."( Evidence for the assignment of GUK 1 gene locus to 1q32 leads to q43 segment from gene dosage effect.
Dacha, M; Dallapiccola, B; Falorni, A; Lungarotti, MS; Magnani, M, 1980
)
"001) for the duration of the dosing period."( Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
Crozier, IG; Espiner, EA; Frampton, C; Ikram, H; Kosoglou, T; Nicholls, MG; Rallings, M; Richards, AM; Yandle, TG, 1993
)
" Dose-response curves were generated to evaluate endothelium-dependent and endothelium-independent vasoreactivity, ex vivo."( A mouse model of hypercholesterolemia-induced erectile dysfunction.
Annex, BH; Donatucci, CF; Odronic, SI; Pippen, AM; Wu, F; Xie, D, 2007
)
" Dose-response modelling of steady-state predose CSF cyclic guanosine monophosphate concentrations showed ≥200% increase from baseline is maintained with doses of ≥50 mg QD."( Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial.
Aluri, J; Boyd, P; Horie, K; Ino, M; Lai, R; Landry, IS; Reyderman, L; Schuck, E,
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
biomarkerA substance used as an indicator of a biological state.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
guanosine 5'-phosphate
purine ribonucleoside 5'-monophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (26)

PathwayProteinsCompounds
guanine and guanosine salvage II17
guanine and guanosine salvage III010
purine nucleosides salvage II (plant)419
guanosine nucleotides degradation II125
guanosine ribonucleotides de novo biosynthesis215
superpathway of purines degradation in plants745
superpathway of guanosine nucleotides degradation (plants)227
guanosine nucleotides degradation I226
purine nucleotides degradation I (plants)334
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
GMP + Pyrophosphate = Guanine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
ATP + GMP = ADP + GDP ( Purine nucleotides and Nucleosides metabolism )14
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Sildenafil treatment07
lipophosphoglycan (LPG) biosynthesis012
salvage pathways of purine nucleosides021
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
purine and pyrimidine metabolism032
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
purine nucleotides de novo biosynthesis II033
salvage pathways of guanine, xanthine, and their nucleosides017
salvage pathways of purine nucleosides I027
Biochemical pathways: part I0466
Phosphodiesterases in neuronal function013

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Hypoxanthine PhosphoribosyltransferaseEscherichia coliKi526.0000247.0000386.5000526.0000AID977610
Chain A, HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASEEscherichia coliKi526.0000247.0000386.5000526.0000AID977610
Purine nucleoside phosphorylaseHomo sapiens (human)Ki1,500.00000.00000.52897.0000AID1136403
Hypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)Ki5.80000.60005.54678.9800AID1226509; AID421027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASEToxoplasma gondii RHKd7.10007.100034.050061.0000AID977611
Chain B, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASEToxoplasma gondii RHKd7.10007.100034.050061.0000AID977611
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASEToxoplasma gondii RHKd7.10007.100034.050061.0000AID977611
Chain A, Xanthine phosphoribosyltransferaseBacillus subtilisKd4.50004.50004.50004.5000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
urate biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of T cell proliferationPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationPurine nucleoside phosphorylaseHomo sapiens (human)
allantoin metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nucleobase-containing compound metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyinosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyadenosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
purine ribonucleoside salvagePurine nucleoside phosphorylaseHomo sapiens (human)
IMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nicotinamide riboside catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
immune responsePurine nucleoside phosphorylaseHomo sapiens (human)
nucleotide biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
response to xenobiotic stimulusPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of interleukin-2 productionPurine nucleoside phosphorylaseHomo sapiens (human)
purine-containing compound salvagePurine nucleoside phosphorylaseHomo sapiens (human)
dAMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
T cell mediated cytotoxicityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
response to amphetamineHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine nucleotide biosynthetic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine ribonucleoside salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
locomotory behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
striatum developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cerebral cortex neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
central nervous system neuron developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
positive regulation of dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP catabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
adenine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
lymphocyte proliferationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dendrite morphogenesisHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein homotetramerizationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopaminergic neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
regulation of DNA-templated transcriptionHistidine triad nucleotide-binding protein 1Homo sapiens (human)
proteolysisHistidine triad nucleotide-binding protein 1Homo sapiens (human)
signal transductionHistidine triad nucleotide-binding protein 1Homo sapiens (human)
purine ribonucleotide catabolic processHistidine triad nucleotide-binding protein 1Homo sapiens (human)
protein desumoylationHistidine triad nucleotide-binding protein 1Homo sapiens (human)
positive regulation of calcium-mediated signalingHistidine triad nucleotide-binding protein 1Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorHistidine triad nucleotide-binding protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
nucleoside bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine nucleobase bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine-nucleoside phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
phosphate ion bindingPurine nucleoside phosphorylaseHomo sapiens (human)
identical protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
guanosine phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
nucleotide bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
magnesium ion bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
nucleotide bindingHistidine triad nucleotide-binding protein 1Homo sapiens (human)
protein kinase C bindingHistidine triad nucleotide-binding protein 1Homo sapiens (human)
protein bindingHistidine triad nucleotide-binding protein 1Homo sapiens (human)
hydrolase activityHistidine triad nucleotide-binding protein 1Homo sapiens (human)
deSUMOylase activityHistidine triad nucleotide-binding protein 1Homo sapiens (human)
adenosine 5'-monophosphoramidase activityHistidine triad nucleotide-binding protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular regionPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
cytosolPurine nucleoside phosphorylaseHomo sapiens (human)
secretory granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
extracellular exosomePurine nucleoside phosphorylaseHomo sapiens (human)
ficolin-1-rich granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
nucleusHistidine triad nucleotide-binding protein 1Homo sapiens (human)
nucleoplasmHistidine triad nucleotide-binding protein 1Homo sapiens (human)
cytoplasmHistidine triad nucleotide-binding protein 1Homo sapiens (human)
cytosolHistidine triad nucleotide-binding protein 1Homo sapiens (human)
cytoskeletonHistidine triad nucleotide-binding protein 1Homo sapiens (human)
plasma membraneHistidine triad nucleotide-binding protein 1Homo sapiens (human)
extracellular exosomeHistidine triad nucleotide-binding protein 1Homo sapiens (human)
histone deacetylase complexHistidine triad nucleotide-binding protein 1Homo sapiens (human)
nucleusHistidine triad nucleotide-binding protein 1Homo sapiens (human)
cytoplasmHistidine triad nucleotide-binding protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID767224Inhibition of Escherichia coli HPRT expressed in Escherichia coli SPhi606 using hypoxanthine as substrate by spectrophotometric analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents.
AID1136403Competitive inhibition of human erythrocyte purine nucleoside phosphorylase assessed as inhibition of guanosine phosphorylysis after 30 mins by Lineweaver-Burk plot analysis1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Stereoelectronic factors in the binding of substrate analogues and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes.
AID1172275Inhibition of human recombinant alpha1,3-fucosyltransferase 9 using GDP-[14C]-fucose preincubated for 30 mins by liquid scintillation counting2014Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22
Synthesis and analysis of potential α1,3-fucosyltransferase inhibitors.
AID421026Inhibition of Plasmodium falciparum recombinant HGXPRT expressed in Escherichia coli at pH 7.4 by spectrophotometric assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.
AID767229Binding affinity to Escherichia coli XGPRT2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents.
AID1136399Activity of human erythrocyte purine nucleoside phosphorylase assessed as ribose relase at 5 umol after 30 mins by orcinol reaction relative to guanosine1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Stereoelectronic factors in the binding of substrate analogues and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes.
AID1226510Inhibition of Escherichia coli HGPRT2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.
AID1226509Inhibition of human HGPRT2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.
AID421027Inhibition of human recombinant HGPRT at pH 7.4 by spectrophotometric assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.
AID767225Inhibition of Escherichia coli recombinant XGPRT mutant expressed in Escherichia coli SPhi606 using guanine as substrate by spectrophotometric analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents.
AID1172276Inhibition of Helicobacter pylori recombinant alpha1,3-fucosyltransferase using GDP-[14C]-fucose preincubated for 30 mins by liquid scintillation counting2014Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22
Synthesis and analysis of potential α1,3-fucosyltransferase inhibitors.
AID1226508Inhibition of Mycobacterium tuberculosis HGPRT2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.
AID1136402Inhibition of human erythrocyte purine nucleoside phosphorylase assessed as inhibition of guanosine phosphorylysis at 1.25 umol after 30 mins by orcinol reaction1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Stereoelectronic factors in the binding of substrate analogues and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes.
AID421028Selectivity ratio of Ki for human recombinant HGPRT to Ki for Plasmodium falciparum recombinant HGXPRT at pH 7.42009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2006Biochemistry, May-30, Volume: 45, Issue:21
The extraordinary specificity of xanthine phosphoribosyltransferase from Bacillus subtilis elucidated by reaction kinetics, ligand binding, and crystallography.
AID1811Experimentally measured binding affinity data derived from PDB2006Biochemistry, May-30, Volume: 45, Issue:21
The extraordinary specificity of xanthine phosphoribosyltransferase from Bacillus subtilis elucidated by reaction kinetics, ligand binding, and crystallography.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2002Protein science : a publication of the Protein Society, Jul, Volume: 11, Issue:7
Crystal structures of free, IMP-, and GMP-bound Escherichia coli hypoxanthine phosphoribosyltransferase.
AID1811Experimentally measured binding affinity data derived from PDB2002Protein science : a publication of the Protein Society, Jul, Volume: 11, Issue:7
Crystal structures of free, IMP-, and GMP-bound Escherichia coli hypoxanthine phosphoribosyltransferase.
AID1811Experimentally measured binding affinity data derived from PDB1999Biochemistry, Nov-02, Volume: 38, Issue:44
Crystal structures of the Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase-GMP and -IMP complexes: comparison of purine binding interactions with the XMP complex.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1999Biochemistry, Nov-02, Volume: 38, Issue:44
Crystal structures of the Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase-GMP and -IMP complexes: comparison of purine binding interactions with the XMP complex.
AID1811Experimentally measured binding affinity data derived from PDB2004The Journal of biological chemistry, Jun-18, Volume: 279, Issue:25
Crystal structure of transglutaminase 3 in complex with GMP: structural basis for nucleotide specificity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,472)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990430 (29.21)18.7374
1990's334 (22.69)18.2507
2000's348 (23.64)29.6817
2010's260 (17.66)24.3611
2020's100 (6.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (1.31%)5.53%
Reviews49 (3.21%)6.00%
Case Studies3 (0.20%)4.05%
Observational1 (0.07%)0.25%
Other1,453 (95.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]